Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-PIPAC trial in pancreatic cancer with peritoneal metastases
2021-002539-51Phase 2Active
- Sponsor
- Policlinico Gemelli
- Start
- Oct 2021
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel and gemcitabine in pancreatic cancer (PC) and peritoneal carcinomatosis (PC), sponsored by Policlinico Gemelli. Primary endpoint: Antitumoral activity. Started Oct 2021; status: active.
02
Drugs
nab-paclitaxelgemcitabine
03
Conditions
pancreatic cancer (PC)peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on 2021-002539-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002539-51.